A Polypill Strategy to Improve Adherence Results From the FOCUS Project
| العنوان: | A Polypill Strategy to Improve Adherence Results From the FOCUS Project |
|---|---|
| المؤلفون: | Castellano, José M., Sanz, Ginés, Peñalvo, José L., Bansilal, Sameer, Fernández-Ortiz, Antonio, Alvarez, Luz, Guzmán, Luis, Linares, Juan Carlos, García, Fernando, D’Aniello, Fabiana, Arnáiz, Joan Albert, Varea, Sara, Martínez, Felipe, Lorenzatti, Alberto, Imaz, Iñaki, Sánchez-Gómez, Luis M., Roncaglioni, Maria Carla, Baviera, Marta, Smith, Sidney C., Taubert, Kathryn, Pocock, Stuart, Brotons, Carlos, Farkouh, Michael E., Fuster, Valentin |
| المصدر: | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| بيانات النشر: | ELSEVIER SCIENCE INC, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Male, Myocardial Infarction, Cardiovascular Agents, Middle Aged, Medication Adherence, Cohort Studies, Drug Combinations, Cross-Sectional Studies, Cardiovascular Diseases, Secondary Prevention, Humans, Female, Prospective Studies, adherence, secondary prevention, Aged, polypill |
| الوصف: | BackgroundAdherence to evidence-based cardiovascular (CV) medications after an acute myocardial infarction (MI) is low after the first 6 months. The use of fixed-dose combinations (FDC) has been shown to improve treatment adherence and risk factor control. However, no previous randomized trial has analyzed the impact of a polypill strategy on adherence in post-MI patients.ObjectivesThe cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) study (Phase 1) aimed to elucidate factors that interfere with appropriate adherence to CV medications for secondary prevention after an acute MI. Additionally, 695 patients from Phase 1 were randomized into a controlled trial (Phase 2) to test the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) compared with the 3 drugs given separately on adherence, blood pressure, and low-density lipoprotein cholesterol, as well as safety and tolerability over a period of 9 months of follow-up.MethodsIn Phase 1, a 5-country cohort of 2,118 patients was analyzed. Patients were randomized to either the polypill or 3 drugs separately for Phase 2. Primary endpoint was adherence to the treatment measured at the final visit by the self-reported Morisky-Green questionnaire (MAQ) and pill count (patients had to meet both criteria for adherence at the in-person visit to be considered adherent).ResultsIn Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was 45.5%. In a multivariable regression model, the risk of being nonadherent (MAQ |
| تدمد: | 0735-1097 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a872620a58da123f2357b7bafea59788Test https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9127Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid.dedup....a872620a58da123f2357b7bafea59788 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 07351097 |
|---|